Groups

                       Echocardiographic Cardiac Functions

LV end-systolic dimension (LVSD) (mm)

LV end-diastolic dimension (LVDD) (mm)

Ejection fraction (EF) (%)

Fractional shortening (FS) (%)

control saline

2.8±0.015

8.9±0.01

92±1.9

59±1.3

control carvedilol

3±0.03

7±0.015

90±2

56±1.4

control nebivolol

3.2±0.012

6.8±0.02

89±1.6

55±1.1

doxorubicin alone*

9±0.05

12±0.15

63±2.9

30±1.5

dox + carvedilol†

4±0.02

8.8±0.025

80±1.7

51±1.3

dox + nebivolol‡§

4.7±0.014

8.6±0.016

88±2

45±1.6
*All measures of Dox alone group significantly different from control groups p<0.0001 † All measures of Dox-Carvedilol group was significantly different from Dox alone group p<0.05 ‡ All measures of Dox-Nebivolol group was significantly different from Dox alone group p<0.0001 § All measures of Dox-Nebivolol group was significantly different from Dox-Carvedilol group p<0.05
Table 1: Effect of carvedilol and nebivolol on Doxorubicin induced Cardiac Echocardiographic changes. Values are expressed as meanąS.D. (n=8)